Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1261 to 1275 of 2004 results for nice guidelines

  1. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  2. OxyMask for delivering oxygen therapy (MIB160)

    NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .

    Medtech innovation briefing
    Published
    27 September 2018

  3. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

    Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA449

  4. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (HTG549)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.

    HealthTech guidance
    Published
    5 August 2020
    View recommendations

    Sections for HTG549

  5. Hearing loss prevalence in people who under-present for hearing loss:- What is the prevalence of hearing loss among populations who under-present for possible hearingloss?

    consider the possibility of hearing loss.The evidence review for the NICE guideline on adult hearing loss highlighted...

    Research recommendation
    Published
    10 December 2018

  6. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1057

  7. Our principles

    The principles that guide the development of NICE guidance and standards.

  8. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    Surgery for vaginal vault prolapse Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last updated...

  9. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .

    Medtech innovation briefing
    Published
    4 July 2017

  10. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  11. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    22 August 2012
    View recommendations

    Sections for TA263

  12. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

    HealthTech guidance
    Published
    7 August 2013
    View recommendations

    Sections for HTG315

  13. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    26 October 2022
    View recommendations

    Sections for TA837

  14. Public board meeting agenda and papers March 2025

    Agenda and papers of the NICE public board meeting on 19 March 2025

  15. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

    HealthTech guidance
    Published
    26 September 2023
    View recommendations

    Sections for HTG694